IP Library Granted Patent US 8,741,956
Granted Patent B2
US 8,741,956 · App. 13/668,061 · Granted Jun 3, 2014

Treatment of pain with topical diclofenac

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,741,956
App. No.
13/668,061
Granted
Jun 3, 2014
Kind
B2
Abstract

The field involves compositions useful for pain relief, including diclofenac solution and gel formulations, in particular methods of use thereof, articles of manufacture and kits that provide novel preclinical, clinical and other information to users.

Claims (32)

1. A method for treating a patient having pain, said method comprising:

administering a therapeutically effective amount of an oral NSAID along with applying a topical diclofenac preparation to a knee of said patient to treat osteoarthritis, wherein said topical diclofenac preparation comprises a therapeutically effective amount of a diclofenac salt and 40-50% w/w dimethyl sulfoxide; and

informing the patient to conduct periodic laboratory evaluations, wherein the therapeutically effective amount of oral NSAID is the amount required to achieve a therapeutic effect in the absence of applying a topical diclofenac preparation.

2. The method according to claim 1 , further comprising:

conducting periodic laboratory evaluations.

3. The method according to claim 1 , wherein the informing step is by written instruction.

4. The method according to claim 1 , wherein the written instruction is a product insert.

5. The method according to claim 1 , wherein said diclofenac preparation comprises about 45.5% w/w dimethyl sulfoxide.

6. The method according to claim 1 , wherein said diclofenac preparation further comprises ethanol, propylene glycol, glycerine, and water.

7. The method according to claim 1 , wherein said therapeutically effective amount of diclofenac salt comprises a pharmaceutically acceptable salt of diclofenac selected from a sodium salt, a potassium salt, a diethylamine salt, or an epolamine salt.

8. The method according to claim 1 , wherein said therapeutically effective amount of diclofenac is 1.5% w/w diclofenac sodium.

9. The method according to claim 1 , wherein said oral NSAID is a member selected from the group consisting of a COX-2 selective NSAID, diclofenac, tenoxicam, meloxicam, celecoxib, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, and tolmetin.

10. A method for treating a patient with pain, said method comprising:

administering a therapeutically effective amount of an oral NSAID along with applying a topical diclofenac preparation to a knee of said patient to treat osteoarthritis, wherein said topical diclofenac preparation comprises a therapeutically effective amount of a diclofenac salt and 40-50% w/w dimethyl sulfoxide;

informing the patient to conduct periodic laboratory evaluations; and

conducting periodic laboratory evaluations.

11. The method according to claim 10 , wherein the informing step is by written instruction.

12. The method according to claim 11 , wherein the written instruction is a product insert.

13. The method according to claim 10 , wherein said diclofenac preparation comprises about 45.5% w/w dimethyl sulfoxide.

14. The method according to claim 10 , wherein said diclofenac preparation further comprises ethanol, propylene glycol, glycerine, and water.

15. The method according to claim 10 , wherein said therapeutically effective amount of diclofenac salt comprises a pharmaceutically acceptable salt of diclofenac selected from a sodium salt, a potassium salt, a diethylamine salt, or an epolamine salt.

16. The method according to claim 10 , wherein said therapeutically effective amount of diclofenac is 1.5% w/w diclofenac sodium.

17. The method according to claim 10 , wherein said oral NSAID is a member selected from the group consisting of a COX-2 selective NSAID, diclofenac, tenoxicam, meloxicam, celecoxib, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, and tolmetin.

18. A method for treating a patient having pain, said method comprising:

(a) administering a therapeutically effective amount of an oral NSAID along with applying a topical diclofenac preparation to a knee of said patient to treat osteoarthritis, wherein said topical diclofenac preparation comprises a therapeutically effective amount of a diclofenac salt and 40-50% w/w dimethyl sulfoxide; and

(b) conducting periodic laboratory evaluations,

wherein administering, applying, and conducting are performed in accordance with written instructions.

19. The method of claim 18 , wherein the written instruction is a product insert.

20. The method according to claim 18 , wherein said diclofenac preparation comprises about 45.5% w/w dimethyl sulfoxide.

21. The method according to claim 18 , wherein said diclofenac preparation further comprises ethanol, propylene glycol, glycerine, and water.

22. The method according to claim 18 , wherein said therapeutically effective amount of diclofenac salt comprises a pharmaceutically acceptable salt of diclofenac selected from a sodium salt, a potassium salt, a diethylamine salt, or an epolamine salt.

23. The method according to claim 18 , wherein said therapeutically effective amount of diclofenac is 1.5% w/w diclofenac sodium.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2023
From: CITIBANK, N.A.
To: HORIZON THERAPEUTICS IRELAND DAC (SUCCESSOR IN INTEREST TO HORIZON PHARMA SERVICES LIMITED); HORIZON THERAPEUTICS IRELAND DAC (FKA HORIZON PHARMA IRELAND LIMITED); HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.); HZNP LIMITED
Reel/Frame 065153/0953 →
CHANGE OF NAME Recorded Oct 27, 2022
From: HZNP MEDICINES LLC
To: HZNP FINANCE LIMITED
Reel/Frame 061562/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2022
From: HZNP FINANCE LIMITED
To: HORIZON THERAPEUTICS IRELAND DAC
Reel/Frame 061563/0467 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2018
From: HZNP LIMITED
To: HZNP MEDICINES LLC
Reel/Frame 046455/0582 →
SECURITY INTEREST Recorded May 7, 2015
From: HZNP LIMITED
To: CITIBANK, N.A.
Reel/Frame 035591/0061 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2014
From: NUVO RESEARCH INC.
To: HZNP LIMITED
Reel/Frame 034068/0184 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2013
From: SINGH, JAGAT; SHAINHOUSE, JOSEPH ZEV; GALER, BRADLEY S.; GRIERSON, LISA MARIE; BURIAN, MARIA; WILKIN, JONATHAN; KISAK, EDWARD T.; NEWSAM, JOHN M.; KING-SMITH, ROBERT DOMINIC
To: NUVO RESEARCH INC.
Reel/Frame 029598/0806 →